According to data from the UK BioIndustry Association and Clarivate PLC, investment in UK biotech has accelerated by a record-breaking 1,000% since 2012, with companies within the industry generating a record £2.8 billion in equity finance in 2020.
Although much of this newfound investor enthusiasm is down to the arrival of the COVID-19 pandemic and fresh interest in the industry, there appears to be plenty of opportunities for growth within the UK sector, too – with several large deals in the pipeline for 2021 and beyond. The list includes a Sanofi deal to buy Cambridge-based Kymab for $1.45 billion – the largest acquisition of a privately listed UK biotech company on record.
As we can see from the table above, 2020 has been a largely excellent year for biopharma companies choosing to go public, with the majority of floated stocks appreciating by more than 50%.
This level of investor confidence has helped to accelerate the growth of UK biotech companies and has paved the way towards a prosperous future in the industry domestically. But just how big can biotech become…
